| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -18,648 | -12,640 |
| Depreciation | 1,308 | 881 |
| Foreign exchange (gain) loss | 2,163 | 3,365 |
| Share-based compensation expense | 3,460 | 3,436 |
| Income tax receivable | -83 | 0 |
| Accrued interest receivable | -250 | -220 |
| Prepaid expenses and other current assets | 27 | 281 |
| Accounts payable | -1,180 | -795 |
| Accrued expenses | -210 | -222 |
| Income tax payable | 159 | 57 |
| Net cash used in operating activities | -16,968 | -12,709 |
| Purchase of property and equipment | 255 | 145 |
| Net cash (used in) investing activities | -255 | -145 |
| Payment on convertible loan, third party | -10,000 | -10,000 |
| Payment on convertible loan, third party-Nonrelated Party | -250 | -250 |
| Proceeds from issuance of common stock under stock option plan | 0 | 0 |
| Net cash (used in) provided by financing activities | -10,250 | -10,250 |
| Effect of foreign exchange rate on cash and cash equivalents | 2,163 | 3,365 |
| Net change in cash and cash equivalents | -25,310 | -19,739 |
| Cash and cash equivalents at beginning of period | 172,677 | - |
| Cash and cash equivalents at end of period | 147,367 | - |
XBiotech Inc. (XBIT)
XBiotech Inc. (XBIT)